Status of and strategies for improving adherence to COPD treatment
- PMID: 31371936
- PMCID: PMC6628097
- DOI: 10.2147/COPD.S170848
Status of and strategies for improving adherence to COPD treatment
Abstract
Despite the wide application of adherence as a concept, the definition, evaluation and improvement of the adherence to treatment by patients with chronic obstructive pulmonary disease (COPD) still present some challenges. First, it is necessary to clearly define the concepts of treatment adherence, compliance and persistence. Second, it is critical to consider the various methods of evaluating and quantifying adherence when interpreting adherence studies. In addition, the advantages and disadvantages of the different ways of measuring treatment adherence should be taken into account. Another subject of some debate is the number of variables associated with COPD treatment adherence. Adherence is a complex concept that goes beyond the dosage or the use of inhalation devices, and a number of variables are involved in determining adherence, from the clinical aspects of the disease to the patient's confidence in the doctor's expertise and the level of social support experienced by the patient. Notably, despite these challenges, the importance of adherence has been well established by clinical trials and routine clinical practice. The available evidence consistently shows the substantial impact that a lack of adherence has on the control of the disease and its long-term prognosis. For these reasons, the correct evaluation of therapeutic adherence should be a key objective in clinical interviews of patients. In recent years, various initiatives for improving adherence have been explored. All these initiatives have been based on patient education. Therefore, health care professionals should be aware of the issues pertaining to adherence and take the opportunity to educate patients each time they contact the health care system.
Keywords: COPD; adherence; inhaled therapy; medication reminders.
Conflict of interest statement
JLLC has received honoraria for lecturing, providing scientific advice, participating in clinical studies or writing for publications during the last three years for (in alphabetical order): AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Esteve, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Novartis, Rovi, and Teva. The authors report no other conflicts of interest in this work.
Figures


Similar articles
-
Correct use of inhalers for COPD.Med Lett Drugs Ther. 2017 Apr 10;59(1518):e67-e71. Med Lett Drugs Ther. 2017. PMID: 28377554 No abstract available.
-
Drugs for COPD.Med Lett Drugs Ther. 2017 Apr 10;59(1518):57-62. Med Lett Drugs Ther. 2017. PMID: 28377550 No abstract available.
-
Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.Int J Chron Obstruct Pulmon Dis. 2018 May 11;13:1545-1556. doi: 10.2147/COPD.S154097. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29785104 Free PMC article.
-
What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?Expert Rev Respir Med. 2013 Apr;7(2 Suppl):43-51. doi: 10.1586/ers.13.17. Expert Rev Respir Med. 2013. PMID: 23551023 Review.
-
Switching treatments in COPD: implications for costs and treatment adherence.Int J Chron Obstruct Pulmon Dis. 2015 Dec 3;10:2601-8. doi: 10.2147/COPD.S79635. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26664108 Free PMC article. Review.
Cited by
-
FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.Int J Chron Obstruct Pulmon Dis. 2022 May 4;17:1005-1015. doi: 10.2147/COPD.S360938. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35547784 Free PMC article.
-
Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review.Pulm Ther. 2022 Mar;8(1):1-41. doi: 10.1007/s41030-021-00178-1. Epub 2021 Dec 3. Pulm Ther. 2022. PMID: 34860355 Free PMC article. Review.
-
Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.Future Med Chem. 2022 Feb;14(4):271-288. doi: 10.4155/fmc-2021-0081. Epub 2022 Jan 12. Future Med Chem. 2022. PMID: 35019757 Free PMC article. Review.
-
Measuring adherence to therapy in airways disease.Breathe (Sheff). 2021 Jun;17(2):210037. doi: 10.1183/20734735.0037-2021. Breathe (Sheff). 2021. PMID: 34295430 Free PMC article. Review.
-
Association between medication adherence and health-related quality of life in patients with chronic obstructive pulmonary disease.J Pharm Health Care Sci. 2021 Nov 15;7(1):40. doi: 10.1186/s40780-021-00222-x. J Pharm Health Care Sci. 2021. PMID: 34775992 Free PMC article.
References
-
- Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S184653 - DOI - PMC - PubMed
-
- Watts RW, McLennan G, Bassham I, el-Saadi O. Do patients with asthma fill their prescriptions? A primary compliance study. Aust Fam Physician. 1997;26(Suppl 1):S4–S6. - PubMed
-
- Sabaté E, editor. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
-
- Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7–8):1280–1288. - PubMed